Key result
Diabetes linked to ~121% higher composite CV risk in patients with HFpEF.
Why the study?
Data were limited regarding biomarker profiles in HFpEF patients with versus without diabetes, as well as the impact of spironolactone on these biomarkers.
Does spironolactone alter biomarker profiles and clinical outcomes differently in HFpEF patients with versus without diabetes?
Cohort (n=248)
Double-blind
Yes
Does spironolactone alter biomarker profiles and clinical outcomes differently in HFpEF patients with versus without diabetes?
Diabetes in HFpEF is associated with a more profibrotic biomarker profile, and spironolactone may offer targeted anti-remodeling benefits specifically in this subgroup.
Answers are grounded in this paper and cite their sources.
DM-associated risk in HFpEF supports extending HFrEF biomarker observations; hypothesis-generating for spironolactone effects, needs prospective trials.
AIMS: Diabetes mellitus (DM) is common in heart failure with preserved ejection fraction (HFpEF). Patients with DM and heart failure with reduced ejection fraction have higher levels of cardiac, profibrotic, and proinflammatory biomarkers relative to non-diabetics. Limited data are available regarding the biomarker profiles of HFpEF patients with diabetes (DM) vs. no diabetes (non-DM) and the impact of spironolactone on these biomarkers. This study aims to address such gaps in the literature. METHODS AND RESULTS: Biomarkers were measured at randomization and at 12 months in 248 patients enrolled in Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist's North American cohort. At baseline, DM patients had significantly lower estimated glomerular filtration rate and higher high-sensitivity C-reactive protein, pro-collagen type III amino-terminal peptide, tissue inhibitor of metalloproteinase 1 (TIMP-1), and galectin-3 levels than those without diabetes. There was a significantly larger 12 month increase in levels of high-sensitivity troponin T (hs-TnT), a marker of myocyte death, in DM patients. Elevated pro-collagen type III amino-terminal peptide and galectin-3 levels were associated with an increased risk of the primary outcome (cardiovascular mortality, aborted cardiac arrest, or heart failure hospitalization) in DM patients, but not in those without diabetes. A statistically significant interaction between spironolactone and diabetes status was observed for hs-TnT and for TIMP-1, with greater biomarker reductions among those with diabetes treated with spironolactone. CONCLUSIONS: The presence of diabetes is associated with higher levels of cardiac, profibrotic, and proinflammatory biomarkers in HFpEF. Spironolactone appears to alter the determinants of extracellular matrix remodelling in an anti-fibrotic fashion in patients with diabetes, reflected by changes in hs-TnT and TIMP-1 levels over time.
No takes yet. Share an insight, caveat, or question.
Marco et al. (2021) conducted a cohort in Heart failure with preserved ejection fraction (n=248). Diabetes mellitus vs. No diabetes was evaluated on Composite of death from a cardiovascular cause, aborted cardiac arrest, or heart failure hospitalization (HR 2.21, 95% CI 1.37-3.55). Diabetes mellitus was associated with an increased risk of cardiovascular death, aborted cardiac arrest, or heart failure hospitalization in patients with HFpEF compared to no diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: